Novozymes A/S logo

Novozymes A/S

NVZMY | OTC
Chart Builder DCF Calculator
$69.19
+$0.13 (+0.18%)
At close: Nov 2, 2026, 3:59 PM ET
$69.31
+$0.12 (+0.17%)
After-hours: Nov 2, 2026, 4:00 PM ET
Fiscal Year
Period Ending
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Cash & Equivalents
275.3M 280M 1.12B 1.04B 963M 1.18B
Short-Term Investments
20.3M 4M 40M 80M n/a 119M
Long-Term Investments
36.97M 38.7M 227M 347M 29M 94M
Other Long-Term Assets
29.34K 10M 1.87B 46.57M 69M n/a
Receivables
869.4M 804.6M 543.5M 3.61B 2.99B 2.56B
Inventory
772.2M 720.6M 3.63B 3.8B 2.99B 2.36B
Other Current Assets
46M 70.2M 4.14B 538M 805M 695M
Total Current Assets
1.98B 1.88B 9.46B 9.24B 7.82B 6.91B
Property-Plant & Equipment
3B 2.97B 12.33B 12.07B 10.19B 9.61B
Goodwill & Intangibles
11.09B 10.02B 4.53B 4.7B 5.02B 2.55B
Total Long-Term Assets
14.37B 13.32B 18.93B 18.74B 16.94B 13.6B
Total Assets
16.35B 15.2B 28.39B 27.98B 24.77B 20.51B
Account Payables
420.8M 423.1M 1.62B 1.87B 1.49B 1.1B
Deferred Revenue
n/a n/a n/a 2B 2.02B 970M
Short-Term Debt
12.71B 266.4M 3.22B 2.92B 2.14B 1.11B
Other Current Liabilities
-10.5B 337.9M 1.61B -636M -780M 266M
Total Current Liabilities
2.74B 1.09B 7.26B 6.96B 5.67B 4.16B
Long-Term Debt
9.74B 1.53B 4.33B 3.62B 3.68B 3.24B
Other Long-Term Liabilities
52.66M 39.7M 100M 1.1B 2.85B 1.48B
Total Long-Term Liabilities
2.75B 2.93B 6.78B 6.79B 6.89B 5.11B
Total Liabilities
5.49B 4.02B 14.04B 13.76B 12.56B 9.27B
Total Debt
22.45B 1.8B 7.78B 6.95B 482M 4.87B
Book Value
10.86B 11.18B 14.35B 14.23B 12.21B 11.24B
Book Value Per Share
23.25 24.32 51.65 51.05 43.56 39.87
Common Stock
125.5M 125.6M 75.49M 562M 564M 570M
Retained Earnings
11.16B 11.03B 13.76B 13.06B 11.3B 11.26B
Comprehensive Income
-428.46M 17.99M -339M 213M -40M -600M
Shareholders Equity
10.86B 11.18B 13.98B 13.84B 11.83B 11.23B
Total Investments
57.25M 42.7M 267M 427M 29M 213M

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.